Cite
HARVARD Citation
Thompson, G. et al. (n.d.). 1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin. Open forum infectious diseases. pp. S657-S658. [Online].